X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (414) 414
hematology (245) 245
female (205) 205
middle aged (205) 205
male (200) 200
adult (186) 186
oncology (165) 165
aged (142) 142
prognosis (116) 116
leukemia, myeloid, acute - genetics (110) 110
mutation (97) 97
leukemia, lymphocytic, chronic, b-cell - genetics (94) 94
cancer (84) 84
leukemia (80) 80
abridged index medicus (79) 79
survival (76) 76
treatment outcome (75) 75
adolescent (74) 74
aged, 80 and over (73) 73
chromosome aberrations (72) 72
aml (52) 52
expression (52) 52
acute myeloid-leukemia (50) 50
acute myeloid leukemia (47) 47
in situ hybridization, fluorescence (47) 47
leukemia, myeloid, acute - mortality (47) 47
mutations (47) 47
antineoplastic combined chemotherapy protocols - therapeutic use (46) 46
chronic lymphocytic-leukemia (44) 44
young adult (44) 44
genomic aberrations (43) 43
survival analysis (42) 42
survival rate (40) 40
acute disease (37) 37
leukemia, myeloid, acute - therapy (37) 37
acute myelogenous leukemia (36) 36
chemotherapy (36) 36
disease-free survival (36) 36
leukemia, lymphocytic, chronic, b-cell - drug therapy (35) 35
leukemia, myeloid, acute - drug therapy (35) 35
research (35) 35
animals (34) 34
leukemia, lymphocytic, chronic, b-cell - pathology (34) 34
translocation, genetic (34) 34
cd38 expression (32) 32
hemic and lymphatic diseases (32) 32
prospective studies (32) 32
stem-cell transplantation (32) 32
karyotyping (31) 31
leukemia, myeloid, acute - pathology (31) 31
nuclear proteins - genetics (31) 31
diagnosis (30) 30
chromosome deletion (29) 29
gene (29) 29
genetics & heredity (29) 29
leukemia, lymphocytic, chronic, b-cell - mortality (29) 29
apoptosis (28) 28
chronic lymphocytic leukemia (28) 28
cll (28) 28
fludarabine (28) 28
risk factors (28) 28
therapy (28) 28
minimal residual disease (27) 27
follow-up studies (26) 26
gene expression (26) 26
gene expression profiling (26) 26
leukemia, myeloid, acute - diagnosis (26) 26
transplantation (26) 26
antineoplastic combined chemotherapy protocols - adverse effects (25) 25
gene expression regulation, leukemic (25) 25
genetic aspects (25) 25
cell line, tumor (24) 24
fms-like tyrosine kinase 3 - genetics (24) 24
remission induction (24) 24
cohort studies (23) 23
cytogenetics (23) 23
gene deletion (23) 23
leukemia, myeloid - genetics (23) 23
mice (23) 23
stem cells (23) 23
disease progression (22) 22
transplantation, homologous (22) 22
antineoplastic agents - therapeutic use (21) 21
cell biology (21) 21
leukemia, lymphocytic, chronic, b-cell - diagnosis (21) 21
patients (21) 21
rituximab (21) 21
stem cell transplantation (21) 21
adult patients (20) 20
care and treatment (20) 20
classification (20) 20
dna mutational analysis (20) 20
gene expression regulation, neoplastic (20) 20
gene-expression (20) 20
genes (20) 20
kaplan-meier estimate (20) 20
leukemia, lymphocytic, chronic, b-cell - therapy (20) 20
medicine, general & internal (20) 20
mutation - genetics (20) 20
chromosome mapping (19) 19
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2013, Volume 369, Issue 2, pp. 111 - 121
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 370, Issue 12, pp. 1101 - 1110
Journal Article
Nature medicine, ISSN 1546-170X, 2016, Volume 22, Issue 7, pp. 792 - 799
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 5, pp. 454 - 464
Midostaurin, an oral multitargeted kinase inhibitor, is active in patients with a FLT3 mutation. Among patients with acute myeloid leukemia and this mutation,... 
TRIAL | INTERNAL TANDEM DUPLICATION | WILD-TYPE | MEDICINE, GENERAL & INTERNAL | FAVORABLE PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | DISTINCT | TYROSINE KINASE INHIBITOR | SORAFENIB | PHASE-I | YOUNGER | Humans | Middle Aged | Kaplan-Meier Estimate | Staurosporine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Staurosporine - analogs & derivatives | Protein Kinase Inhibitors - adverse effects | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Mutation | Daunorubicin - administration & dosage | Leukemia, Myeloid, Acute - genetics | Staurosporine - administration & dosage | Chemotherapy | Care and treatment | Myelocytic leukemia | Nonlymphoid leukemia | Research | Drug therapy | Cancer | Tyrosine | Medical research | Inhibitor drugs | Myeloid leukemia | Leukemia | Clinical trials | Oncology | Transplantation | Kinases | Patients | Cancer therapies | Survival | Cytarabine | Daunorubicin | Medical prognosis | Point mutation | Death | Remission | Acute myeloid leukemia | Protein-tyrosine kinase | Drug dosages
Journal Article
Journal Article
Journal Article